Image Courtesy: dare2compete.com
Amway India, a direct selling fast-moving consumer goods (FMCG) firm, has been planning to invest ₹170 crore in the next 2-3 years in the country to boost research and development (R&D), manufacturing automation, innovation and science, home delivery and to ensure efficient functioning by strengthening digital capabilities,
Additionally, the company plans to strengthen its nutrition portfolio. The portfolio accounts for over 60 percent in the revenue by exploring adjacent and expanded spaces around the nutrition segment. It displayed a double-digit growth contributing over 61 percent to the business revenue in the year 2020. Out of 140 products in India, the company has around 42 products in the nutrition portfolio.
The CEO of Amway, Anshu Bhudraja has said that moving forward in 2021, the company’s growth will be fuelled by key levers like raising awareness around nutrition and immunity, accelerated digital adaptation and a robust supply chain with seamless last-mile delivery. It will also include innovation products such as an advanced version of the foundation range of supplements, newer formats of engaging products that appeal to the youth and much more.
He added, “We will further strengthen the segment with a huge focus on the herbal category, while also developing some affordable herbal nutrition supplementation.” “With continued demand for nutrition and immunity supplements, we are expanding our nutrition portfolio so as to cater to the evolving consumer demands”, the CEO said. It will develop new products in the traditional herb’s category and look for affordable supplementation space options with new formats.
Amway India had launched Nutrilite Vitamin C Cherry Plus tablets recently. Earlier in 2021, it also launched a Chyawanprash by Nutrilite to strength the immunity supporting portfolio.